Due to high levels of interest and feedback, the FDA is extending the comment period for the much anticipated draft guidance “Labeling for Biosimilar Products; Draft Guidance for Industry; Availability” that was first released on April 4, 2016. The Agency is now accepting comments through August 2, 2016
FDA Extends Comment Period for Biosimilar Labeling Guidance
July 18, 2016